Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
    • State Disclosures
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Cocaine Intoxication
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-801
      • TNX-1800
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Fact Sheet
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Form 8937
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Tonix in the News
  • Tonix Sponsored News
  • IR Events
  • Email Alerts
  • Op-Eds
Mar 21, 2018 4:05pm EDT

Tonix Pharmaceuticals Expands Intellectual Property Portfolio for TNX-102 SL

Mar 13, 2018 7:00am EDT

Tonix Pharmaceuticals to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium

Mar 12, 2018 7:00am EDT

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update

Mar 6, 2018 7:00am EST

Tonix Pharmaceuticals to Present at the 30th Annual ROTH Conference

Feb 15, 2018 7:00am EST

Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors

Feb 7, 2018 4:30pm EST

Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City

Jan 24, 2018 4:30pm EST

Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale

Jan 23, 2018 7:00am EST

Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)

Jan 19, 2018 2:00pm EST

Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture)

Jan 9, 2018 7:00am EST

Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer

  • Previous Pagearrow_back
  • Page 1…
  • …
  • Page 42
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • Page 47
  • Page 48
  • Page 49
  • Page 50
  • Page 51
  • …
  • …Page 69
  • Next Pagearrow_forward
rss_feed News RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2025 Tonix Pharmaceuticals Holding Corp.